{"material": "ARTICLES OF AMENDMENT\n\n\n\nOF\n\n\n\nPHARMACEUTICAL PRODUCT DEVELOPMENT, INC.\n\n\n\nPursuant to \u00a755-10-06 of the General Statutes of North Carolina, the\n\nundersigned corporation hereby submits these Articles of Amendment for the\n\npurpose of amending its Restated Articles of Incorporation.\n\n\n\n| 1. | The name of the corporation is Pharmaceutical Product Development, Inc.\n\n(the \u0093Corporation\u0094).  \n\n---|---|---  \n\n  \n\n| 2. | The following amendment was duly adopted by the Board of Directors on\n\nDecember 30, 2005 pursuant to \u00a755-10-02(4) of the General Statutes of North\n\nCarolina. In accordance with 55-10-02(4) of the General Statutes of North\n\nCarolina, shareholder approval is not required for this amendment.  \n\n---|---|---  \n\n  \n\n| 3. | Article III of the Restated Articles of Incorporation of the\n\nCorporation is hereby amended by deleting the first sentence in its entirety\n\nand inserting the following in lieu thereof:  \n\n---|---|---  \n\n  \n\n\u0093Prior to 12:01 a.m., Eastern Time on February 17, 2006 (the \u0093Split Effective\n\nTime\u0094), the Corporation had the authority to issue One Hundred Million\n\n(100,000,000) shares, Five Million (5,000,000) of which were designated\n\npreferred stock having a par value of $0.10 per share, and Ninety-Five Million\n\n(95,000,000) of which were designated common stock having a par value of $0.10\n\nper share. Effective as of the Split Effective Time, each and every issued and\n\nunissued authorized share of common stock of the Corporation will be\n\nautomatically converted, changed and split into two shares, resulting in the\n\nCorporation having One Hundred Ninety Five Million (195,000,000) authorized\n\nshares, Five Million (5,000,000) of which are designated preferred stock\n\nhaving a par value of $0.10 per share, and One Hundred Ninety Million\n\n(190,000,000) of which are designated common stock having a par value of $0.05\n\nper share.\u0094\n\n\n\n| 4. | These Articles of Amendment will become effective at 12:01 a.m.,\n\nEastern Time on February 17, 2006.  \n\n---|---|---  \n\n  \n\n\n\n* * *\n\n\n\nThis the 7th day of February, 2006.\n\n\n\n|  |  \n\n---|---|---  \n\n  \n\nPHARMACEUTICAL PRODUCT\n\n\n\nDEVELOPMENT, INC.  \n\n  \n\n|  \n\nBy: |  |\n\n\n\n/s/ Fredric N. Eshelman\n\n\n\n* * *  \n\n  \n\n|  | Fredric N. Eshelman, Chief Executive Officer  \n\n  \n\n2\n\n", "completion": {"answer": "N", "reference": ["Article III of the Restated Articles of Incorporation of the Corporation is hereby amended by deleting the first sentence in its entirety and inserting the following in lieu thereof"], "confidence": 4}, "ground_truth": "Y"}